Electra Therapeutics (ETRA) eyes $325 million Nasdaq IPO at $14 to $16

Electra Therapeutics has filed an amended prospectus setting the terms for its initial public offering: 21.7 million shares priced between $14 and $16, pointing to a deal worth roughly $325 million. That scale puts it among the larger biotech raises of the year, a meaningful signal in a market where many clinical-stage companies have struggled to clear the IPO bar at all.

The offering is being led by a heavyweight syndicate of Jefferies, TD Cowen, Evercore ISI, and Cantor. When four bulge-bracket or top-tier specialty banks share the books on a biotech deal of this size, it generally signals strong institutional pre-marketing and a compressed path to pricing.

The amended filing, made public on September 14, 2026, indicates that the company and its underwriters have already gone through at least one round of terms-setting, which is typical as the deal is refined based on early investor feedback during the roadshow. Pricing is expected within days of the amendment becoming public.

The company is set to trade on Nasdaq. Investors watching the biotech IPO pipeline will want to track how the final price lands relative to the $14 to $16 range, as pricing above the midpoint would reflect robust demand while a deal priced at the low end or below would tell a different story about appetite for new clinical-stage issuance.